Axel Ullrich

U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany.

NEO New Oncology GmbH provides molecular diagnostics-based services. Its cancer genome diagnostic platform include The NEO Technology, NEOplus and NEOliquid which support pathologists and oncologists with comprehensive molecular information to help select targeted cancer therapies. The company was founded by Roman Thomas and Axel Ullrich in 2012 and is headquartered in Cologne, Germany.

SciRhom GmbH engages in the development of treatment for life-threatening diseases. The company was founded by Andreas Jenne, Jens Ruhein, Axel Ullrich, Carl Blobel and Matthias Schneider in 2016 and is headquartered in Planegg, Germany.

Axxima Pharmaceuticals AG provided drug discovery and development services. It was a drug discovery company in the field of kinase inhibition. It specialized in kinase-based drug discovery aimed at treating certain forms of cancer. It had also focussed on on HIV, Hepatitis C, tuberculosis and one particular herpes virus infections. The company was headquartered in Munich, Germany.

Cryptome Pharmaceuticals Ltd is a globally-linked, Melbourne-based biotechnology company created to discover and develop effective and safe protein-derived medicines targeting cancer, cardiovascular disease and chronic inflammatory disorders using a proprietary proteomics-based technology platform.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY.

Part of Evotec SE, Evotec (München) GmbH is a German company that provides manufacturing and research support services for pharmaceutical and biotechnology companies. The company is based in Neuried, Germany. The CEOs are Dirk Ullmann, Loëtitia Edith Rouxel. The company was founded in 2005 by Axel Ullrich, Hellmut Kirchner, Henrik Daub. Evotec (München was acquired by Evotec SE on April 19, 2011 for $20.40 million.